Metabolic remodeling agents show beneficial effects in the dystrophin-deficient \textit{mdx} mouse model

Vanessa E Jahnke$^1$, Jack H Van Der Meulen$^1$, Helen K Johnston$^{1,2}$, Svetlana Ghimbovschi$^1$, Terrence Partridge$^{1,2}$, Eric P Hoffman$^{1,2}$ and Kanneboyina Nagaraju$^{1,2,3}$

Abstract

**Background:** Duchenne muscular dystrophy is a genetic disease involving a severe muscle wasting that is characterized by cycles of muscle degeneration/regeneration and culminates in early death in affected boys. Mitochondria are presumed to be involved in the regulation of myoblast proliferation/differentiation; enhancing mitochondrial activity with exercise mimetics (AMPK and PPAR-delta agonists) increases muscle function and inhibits muscle wasting in healthy mice. We therefore asked whether metabolic remodeling agents that increase mitochondrial activity would improve muscle function in \textit{mdx} mice.

**Methods:** Twelve-week-old \textit{mdx} mice were treated with two different metabolic remodeling agents (GW501516 and AICAR), separately or in combination, for 4 weeks. Extensive systematic behavioral, functional, histological, biochemical, and molecular tests were conducted to assess the drug(s') effects.

**Results:** We found a gain in body and muscle weight in all treated mice. Histologic examination showed a decrease in muscle inflammation and in the number of fibers with central nuclei and an increase in fibers with peripheral nuclei, with significantly fewer activated satellite cells and regenerating fibers. Together with an inhibition of FoXO1 signaling, these results indicated that the treatments reduced ongoing muscle damage.

**Conclusions:** The three treatments produced significant improvements in disease phenotype, including an increase in overall behavioral activity and significant gains in forelimb and hind limb strength. Our findings suggest that triggering mitochondrial activity with exercise mimetics improves muscle function in dystrophin-deficient \textit{mdx} mice.

**Keywords:** Duchenne muscular dystrophy, Muscle, AICAR, GW501516, Metabolism
patients recommend that ambulatory and early non-ambulatory-stage boys participate in regular submaximal functional activities [11]. The molecular mechanisms by which exercise provides beneficial effects are currently unclear. However, increased PPARδ and AMPK activities have been implicated in these beneficial effects [12]. We hypothesized that exercise mimetics activating PPARδ and AMPK pathways are beneficial to dystrophin deficient skeletal muscle. In the present study, we have used agonists of PPARδ (GW501516) and AMPK (AICAR) to activate beneficial endurance exercise-induced signaling pathways in mdx mice. We have demonstrated that endurance mimetics can improve muscle function by halting the cycle of muscle regeneration/degeneration in dystrophin-deficient mice.

Methods

Animal experiments

All mice were handled according to Washington DC Veterans Affairs Medical Center’s Institutional Animal Care and Use Committee guidelines under approved protocol # 01079. C57BL/10ScSn-Dmd<sup>mdx</sup>/J (mdx) 8-week-old male mice, 20-30g, were purchased from The Jackson Laboratory housed in an individually vented cage system (with a 12-h light–dark cycle, standard mouse chow and water ad libitum). Mice were rested for 10–14 days, acclimatized on the behavioral instrument for 1 week and then baseline grip strength and behavioral activity was performed. At 12 weeks of age, the mice were given AICAR (250mg/kg [80μl]; Alexis) by intraperitoneal injection and/or GW501516 (7.5mg/kg [80μl]; Alexis) by oral gavage, 5 days/week for 4 weeks. DMSO in PBS (1/2 vol/vol) was used as a vehicle control for all treatments.

Measurement of contraction properties

Mice were anesthetized with 100mg/kg ketamine and 10mg/kg xylazine. EDL muscle was isolated and placed in Ringer’s solution (137mM NaCl, 24mM NaHCO<sub>3</sub>, 11mM glucose, 5mM KCl, 2mM CaCl<sub>2</sub>, 1mM MgSO<sub>4</sub>, 1mM Na<sub>2</sub>PO<sub>4</sub>, and 0.025mM tubocurarine chloride) maintained at 25°C and bubbled with 95% O<sub>2</sub>-5% CO<sub>2</sub>. Contractile properties were measured according to Brooks et al. [13], using an in vitro test apparatus (model 305B, Aurora Scientific). A fatigue protocol was performed (20 min, 100 Hz). EDL muscle was subjected to a series of 120 isometric tetanic contractions (400 ms).

Behavioral activity measurement and grip strength testing

All animals were weighed before and after drug treatment. Grip strength and open-field activity were assessed using a grip strength meter (Columbus Instruments, Columbus, OH) and open-field Digiscan apparatus (Omnitech Electronics, Columbus, Ohio), respectively, as described previously [14]. Tissues were either embedded in OCT or wrapped in foil and then frozen in isopentane chilled in liquid nitrogen. Blood was collected by cardiac puncture, and serum was collected by centrifuging blood for 10min at 10,000rpm and then stored at −80°C.

Muscle cell extraction

Leg muscles that were not harvested as previously described were used for satellite cell extraction. Tendons and aponeuroses were removed. Muscles were minced, placed in digestion medium (2.4U/ml dispase II, 100mg/ml collagenase A), vortexed, and incubated at 37°C. After digestion, tubes were placed on ice, and 25ml of DMEM-1% PS-2% L-Glut were added. The mixture was filtered with a 100-μm cell strainer and centrifuged (800g, 4°C, 3min). The pellet was resuspended in 25ml DMEM-1% PS-2% L-Glut, filtered with a 70-μm cell strainer, and centrifuged (800g, 4°C, 3min). The same operation was repeated with a 40-μm cell strainer. Cell extracts were frozen and stored at −80°C.

Flow cytometry analyses

Mitochondrial content and inner membrane potential (ΔΨ) were assessed with NAO and 3,3′-dihexyloxacarbocyanine iodide (DiOC<sub>6</sub>) (Invitrogen) as described [15]. Cell immunoreactivity against MyoD (Dako) was assessed with Hoechst 33342 (Sigma) as described [15]. Cells were analyzed on a FACSCalibur (BD Biosciences, San Jose, CA, USA) with BD Cell Quest ProTM 4.0.2.
Mitochondrial DNA to nuclear DNA ratio analysis
Total DNA was extracted from muscle cells using DNeasy blood and tissue kit (Qiagen). The content of mtDNA was calculated using real-time quantitative PCR by measuring the threshold cycle ratio (ΔCt) of a mitochondrial-encoded gene (ND1, forward 5’-GGA CCT AAG CCC AAT AAC GA-3’, reverse 5’-GCT TCA TTG GCT ACA CCT TG-3’) versus a nuclear-encoded gene (Beta-globulin, forward 5’-CTT CTG GCT ATG TT TCC CCC TT-3’, reverse 5’-GTT CTC AGG ATC AGG ATC CA-3’).

NADH activity
Frozen sections were incubated in working solution (8mg/5ml NADH and 10mg/5ml NBT, 30 min, 37°C) Sections were rinsed thrice in water, with three exchanges each in 30, 60, and 90% acetone solution, then incubated in 90% acetone until a faint purplish cloud was seen over each section. Sections were then rinsed several times with water and mounted. All sections were stained at the same time to avoid experimental variation. Pictures were analyzed using ImageJ.

Immunohistochemistry and cytokine analysis
Isolated muscle cells and frozen sections were fixed in ethanol (except for developmental myosin heavy chain [dMHC] staining), rinsed, and incubated (30 min, 20°C) with blocking solution (PBS, 2% BSA, 0.5% Triton X-100, 0.1% Tween 20, 20% sheep serum). Samples were washed and incubated with dMHC (DSHB), MyoD (Dako), or IgM overnight at 4°C, then washed and incubated for 60 min (20°C) with the appropriate secondary antibody and Hoechst 33342 (9.0μM, 10 min) and analyzed as described above.

Cytokine expression in EDL muscle lysate was assessed by flow cytometry with a Mouse Inflammation Kit (BD Biosciences 552364), as described in the manufacturer’s instructions.

Hematoxylin and eosin (H&E) staining and fibrosis measurement
EDL muscle sections were stained with H&E. The following parameters were assessed: the number of total fibers present, total fibers with central nuclei, total peripheral nuclei (dark-blue nuclei), total central nuclei, regenerating fibers (purple), degenerating fibers (pale pink), and inflammation (an interstitial group of 10 smaller inflammatory cells with dark-blue nuclei in a field) in five non-overlapping fields in each EDL muscle section. Fibers intersecting the left and top borders of the field were not counted, and nuclei farther than one nuclear diameter from the fiber border were considered central nuclei. Frozen sections were stained with Van Gieson stain (Sigma-Aldrich, St. Louis, MO). Sections were imaged (bright field, 4x objective, Olympus C.A.S.

T. Stereology System, Olympus America Inc., Center Valley, PA). Pictures were processed using ImageJ. Fibrotic red areas were expressed as a percentage of the total tissue section.

Western blotting
Protein homogenates were extracted as previously described [16]. Proteins were separated on 4-12% Nupage Bis/Tris gels. After electro transfer, membranes were saturated with 5% non-fat dry milk (1h, 20°C) and incubated overnight with primary antibody against FoxO1 (1/1,000) (cell signaling), utrophin A (1/1,000) (DSHB), or vinculin (1/10,000) (Sigma), then with the corresponding secondary antibodies (1/5,000) (Dako) for 90 min. Immunoreactivity was determined by chemiluminescence and quantified with Quantity One (Bio-Rad).

RNA extraction and MiRNA gene expression
RNA was extracted using an miRNeasy Mini Kit (Qiagen, Valencia, CA). Reverse transcription (RT) was performed with a TaqMan microRNA reverse transcription kit (Life Technologies Co., Applied Bysystems, Carlsbad, CA). miRNA expression was calculated using real-time quantitative PCR by measuring the threshold cycle ratio (ΔCt) of miRNA31l (3’-AGGCAAGAGCUGGCAUGCG-5’) and miRNA133a (3’-UUUGUCCCCUUCACACGC-5’) versus endogenous control snORNA202 (3’-GCUUG UACUGAC UUGAUGAAGAUCU UGA-5’). mRNA expression was calculated using real-time quantitative PCR by measuring the threshold cycle ratio (ΔCt) of PGC-1α mRNA (5’-CGGC CGA GTT CTT GTA A 3’, 5’-GCC AGA TTG GCT TGT TTG G 3’), cyt c mRNA (5’-TGC CCA GTG CCA CAC TGT 3’, 5’-CTG TCT TCC GCC CGA ACA 3’), PDK-4 mRNA (5’-CCG CTG CCG ATG ACA C 3’, 5’-GCA GAA AAG CAA AGG ACG TT 3’) versus endogenous control GAPDH mRNA (5’-CCG TTC AGC TCT GGG ATG AC 3’, 5’-TTC TCA GCA ATG CAT CTT GC 3’).

Statistical analyses
The mean difference between treated and untreated mice was determined by one-way analysis of variance. Scheffé’s post hoc test was used to identify specific mean differences.

Results
Effect of dystrophin deficiency on mitochondrial metabolism
Evaluation of mitochondrial mass (NAO staining) in EDL fibers of mdx mice and WT control mice (Figure 1A) showed that dystrophin-deficient muscle fibers have decreased mitochondrial mass, indicating that these muscle have a lower capacity to use oxidative energy. Furthermore, assessment of LDH activity (Figure 1B)
demonstrated that the *mdx* mice had a greater capacity to produce lactate. These muscles also showed lower specific force than those of WT mice (Figure 1C), and fatigue testing showed that dystrophin-deficient muscle was more fatigable than that of WT mice (Figure 1D), suggesting that dystrophin deficiency leads to significant alterations in mitochondrial function and muscle metabolism. Comparison of the ratio of mtDNA to nDNA in the gastrocnemius muscle of vehicle treated and drug treated groups also suggested a trend in an increase of the mtDNA in the AICAR and combination groups (data not shown).

**Effect of GW and AICAR on muscle weight and behavioral activity measures**

The average body mass of the treated mice was significantly higher than that of vehicle-treated mice (Figure 2A). Treatments increased the body mass by ~10% (GW, 9.2%; AICAR, 11.3%; GW&AICAR, 10.63%). A general increase in the weight of the EDL, gastrocnemius, quadriceps, soleus, and TA muscles was found in the drug-treated groups (statistically significant for the quadriceps (GW, +12.7%; AICAR, +14.6%; GW&AICAR, 13.7%) (Figure 2B) and soleus (GW, +14.3%; AICAR, +17.4%) (Figure 2C). Interestingly, abdominal fat was decreased in response to all three treatments (Figure 2D), and the decrease was statistically significant for both single-treatment groups.

Grip strength and open-field animal activity tests were performed before and after drug treatment. We found a significant increase in forelimb grip strength in the GW501516-treated and combination-treatment groups (Figure 2E,F). The increase in hind limb grip strength was significant for all three treatments (Figure 2G). Since these drugs influenced body weight, we normalized data to body weight. Both forelimb and hind limb grip strength increased significantly with GW501516 (+19%, +13%, respectively) and combination treatment (+25%, +13%, respectively) (Figure 2F). Behavioral activity measures did not significantly change for the single treatments but the combination treatment group showed significantly increased movement time (89%) (Figure 2I).
and decreased rest time (Figure 2J), suggesting an overall beneficial effect on these parameters.

**Effect of GW and AICAR on mitochondrial activity**

We evaluated the impact of these drugs on mitochondrial activity in muscle cells isolated from hind limb muscles of dystrophin-deficient mdx mice. A significant increase in mitochondrial mass, as indicated by NAO staining, was found in the GW501516-treated cells (Figure 3A,B). We saw no significant increase in either the AICAR- or combination-treated groups. Mitochondrial ΔΨ, as assessed by DiOC6 staining, was significantly increased in response to AICAR treatment (Figure 3C,D) but not GW501516 or combination treatment. Gastrocnemius muscle from treated mdx mice expressed significantly more PGC-1α, cyt c mRNAs (Figure 3E,F) in comparison to vehicle treated group but increase in PDK4 mRNA did not reach statistical significance (Figure 3G). We also found that NADH activity was significantly increased in EDL (Figure 3H) (GW, +43%; AICAR, +29%; GW&AICAR, +26%) and SOL (Figure 3I) muscle (GW, +35%; AICAR, +26%; GW&AICAR, 13.7%) in response to drug treatment. Soleus muscles expressed more myosin heavy chain type I (Figure 3J), whereas only GW showed a statistically significant increase in type IIA fibers (Figure 3K). This increase in oxidative capacity was also observed in EDL muscles, in which the ratio of the height of the twitch force (Pt) to the time to reach this maximal force (tpt) was increased in single-treated mice (GW, +18%; AICAR, +24%) (Figure 3L). Finally, LDH activity in the TA was decreased in all three treatment groups, but the decrease was only statistically significant for GW-treated mice (~30%) (Figure 3M).

**Effect of GW and AICAR on satellite cell activation and muscle regeneration and degeneration**

We found that the number of dMHC-positive fibers was significantly decreased in the drug-treated groups
(Figure 4A,B), and MyoD expression in isolated skeletal muscle cells was markedly decreased in the GW- and combination-treated groups (Figure 4C). Furthermore, the number of EDL fibers without central nucleation increased in the single-treated groups (Figure 4D). Importantly, miRNA31a expression, known to be associated with muscle regeneration/degeneration, was significantly down-regulated in diaphragms of treated mice (GW, -28%; AICAR, -63%; GW&AICAR, -67%) (Figure 4E). miRNA133 was also increased in the treated groups, but the differences did not reach statistical significance (data not shown). Expression of FoXO1, which controls muscle wasting, was decreased in AICAR (-34%) and combination drug-treated mice (-36%) (Figure 4F). Serum CK levels showed huge variations but no statistically significant changes (data not shown). Finally, IgM immunostaining was significantly decreased in gastrocnemius sections of treated muscle (GW, -48%; AICAR, -69%; AICAR&AICAR, -71%) (Figure 4G).
GW&AICAR, -54%) (Figure 4G). Overall, these data suggested a strong reduction in muscle degeneration.

**Effect of GW and AICAR on diaphragm fibrosis, utrophin A expression, muscle cytokines, and inflammation**

Utrophin expression in skeletal muscle was studied because some of these improvements may have been due to utrophin expression [17]. The level of utrophin A was significantly increased in the treated groups over that in untreated mice (GW, +112.97%; AICAR, +84.97%; GW&AICAR, +94.19%) (Figure 5A). We also measured fibrosis in the diaphragm which occurs early in the disease and serves as a useful marker for assessing disease progression and response therapy. We found that the red-positive area was significantly decreased in the treated groups (GW501516, -25.6%; AICAR, -27.5%; GW&AICAR, -27.2%) (Figure 5B). Evaluation of cytokine expression in TA muscle lysate revealed that mdx mice had significantly increased IL-6 and IL-10 levels. Drug treatment did not significantly affect IL-6 expression (Figure 5C), but IL-10 levels were significantly decreased in GW&AICAR-treated mice (-45%) (Figure 5D), and not in individual drug-treated mice. EDL muscle demonstrated a statistically significant decrease in inflammatory infiltrates in the GW group but not the other two groups (Figure 5E).
Discussion
In this study, we have demonstrated that dystrophic muscle displays mitochondrial dysfunction similar to that in golden retriever muscular dystrophy [18]. Metabolic impairment has previously been reported [19], and dystrophin-deficient myoblasts have been described as having a pronounced respiratory impairment [20]. This deficiency is not the primary cause of muscle weakness in dystrophin deficiency; however, it may play a significant additional role that can be important for the time course of the disease. Defects in fatty acid oxidation leads to the accumulation of fatty acylCoA and diacylglycerol, inducing insulin signaling disruption and causing muscle atrophy [21]. Similarly, alterations in mitochondrial functions caused by mtDNA mutations are involved in muscle loss during aging [22]. Mitochondrial fission and remodeling also contribute to muscle atrophy in mice [23]. Conversely, oxidative capacity activation decreases muscle wasting in most cases [10]. Recently, PPARδ have been demonstrated to be involved in satellite cells proliferation and muscle regeneration [24]. Moreover, PGC-1α overexpression inhibits muscle atrophy during fasting and denervation [3] and significantly improves dystrophic muscle [25]. Grumati et al. have demonstrated that correcting mitochondrial impairment in collagen VI deficiency significantly improves muscle function [26]. Therefore, strategies that target mitochondrial up-regulation may be beneficial to dystrophic muscle.

In the present study, we have used two known endurance-mimetic drugs, AICAR and GW501516, to activate endurance exercise-induced signaling pathways. AICAR is a mimic of endurance training that activates AMPK activity, an energy status sensor in the cell [27].

**Figure 5** Effect of GW and AICAR on diaphragm fibrosis, utrophin A expression, muscle cytokines, and inflammation. (A) Western blotting for utrophin in EDL muscles from vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8), and GW&AICAR-treated (n = 6) mice. Vinculin was used as an internal control for protein loading. The expression was normalized to that of vinculin and expressed as a percentage of the vehicle expression. (B) Van Gilson staining of the diaphragms of mice treated with vehicle, GW501516, AICAR, or GW&AICAR. The percentage of fibrosis was then calculated by measuring the area of the fibrosis and the area of the whole section from vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8), and GW&AICAR-treated (n = 6) mice. IL-6 (C) and IL-10 (D) analyses were performed by flow cytometry on EDL muscle lysate (n = 2), with 30,000 events per tube. WT muscle was used as a control for cytokine expression. (E) Inflammation was also analyzed by Histologic examination after H&E staining (1 inflammation = a cluster of 10 nuclei). Data are means ± SE. * P < 0.05 vs. vehicle-treated control mice. **P < 0.01 vs. vehicle-treated control mice.
In normal mice, intraperitoneal injection of AICAR raises the level of PGC-1α expression and increases mitochondrial biogenesis in muscle [28], reducing muscle fatigability and increasing muscle performance [12]. GW501516 is a PPARδ/β agonist, a transcription factor that is co-activated by PGC-1α. Like AICAR, this drug is known to increase the amount of mitochondria and promote mitochondrial metabolism [29,30] and fatty acid oxidation [31] in vivo and in vitro and has been tested as a therapeutic for type II diabetes [29,31,32]. More interestingly, the increase in muscle performance that is stimulated by PPARδ/β activity is independent of exercise training in mice [33] and combination treatments with these drugs have been shown to have synergistic beneficial effects in vivo in WT mice [12].

Our study clearly demonstrates that endurance mimetics improve muscle function and overall activity in dystrophic mice. The stimulation of mitochondrial biogenesis by GW501516 and/or AICAR that we have observed is consistent with previous studies [31,33-35]. Miura et al. reported the use of GW501516 to slow the myogenic program and increase utrophin A expression in 5 weeks old mdx mice. More recently, Ljubicic et al. have reported that AICAR supplementation accompanied with bout of exercise also improve muscle function in 5 weeks old MDX mice. In our study, we have further shown a decrease in LDH activity in TA muscles and increase in NADH activity, together with an increase in type I/IIA fibers in soleus muscle, an increase of mRNA expression of PGC-1α, cyt c and a trend for PDK-4 suggesting that the phenotype of treated muscle shifts from glycolytic to oxidative type. Recently, Selsby et al. found that enhancing PGC-1α expression rescues dystrophic muscle and that a switch from fast- to slow-twitch muscle is involved [25]. Moreover, utrophin expression increased, as also shown in our study, and could be part of the process of improving muscle function. Evidence suggests that utrophin is likely to compensate for the lack of dystrophin in DMD muscle [17,36] and to decrease muscle pathology [37,38]. This suggests the possibility that the increase of Utrophin A might partly restore the dystrophin associated glycoprotein and help to improve muscle function. Slow-twitch fibers have been reported to have higher utrophin expression than do fast-twitch fibers. Therefore, the increase in utrophin expression with treatment could be a result of the change in fiber metabolism. The presence of fibers with no central nuclei and the increase in peripheral nuclei suggest that degeneration/regeneration has been halted by this therapeutic intervention. This evidence is further corroborated by the concomitant down-regulation of activated satellite cells and dMHC-positive regenerated fibers and a decrease in miRNA-31, which are involved in muscle degeneration [39]. Stabilization of myofiber structure is suggested by a marked decrease in FoXO1 and IgM expression in fibers. Together, these results clearly indicate that muscle degeneration is decreased in treated mice. FoXO1 transcription is lower in high-oxidative mouse soleus than in low-oxidative gastrocnemius, TA, and quadriceps muscles [40]. In vivo, FoXO1 inhibits high oxidative fiber-related gene expression and oxidative metabolism-enhancing factor activity [41]. Skeletal muscles of FoXO1-over-expressing mice had fewer type I fibers, as well as smaller type I and type II fibers [41]. The phenotype of our treated mice became more oxidative, consistent with this change. A decrease in muscle degradation could explain the diminution in satellite cell activation that we observed.

We also found a decrease in inflammation and fat tissue in the treated mice. Increased IL-6 levels are involved in metabolic and structural changes in muscle and in muscle loss during cachexia [42]. However, IL-6 inhibition has significantly reversed skeletal muscle wasting in rodents [42]. Our data suggest that also GW501516 and AICAR improve muscle function through inflammation down-regulation. Adipose tissue plays a crucial endocrine role through the production of adipokines. Aberrant intracellular signaling cascades that regulate both inflammatory and immune processes are known to contribute substantially to degeneration [43,44]. Therefore, fat reduction is very interesting, since it can reduce inflammation and have an impact on both degeneration and regeneration. GW501516 has been shown to be involved in inflammatory pathway regulation [45]. However, further experiments are needed to delineate the link between proinflammatory fat tissue and muscle inflammation.

Conclusions

In summary, this study demonstrates that the use of endurance mimetics in mdx mice induces an improvement in the structural integrity and reduces the degeneration/regeneration of mdx mouse muscle, probably through an increase in oxidative metabolism in the fibers. Our study and other recent work underline the high potential of pharmacological activators of AMPK and PPARδ as part of rational drug treatments for muscular dystrophies.

Abbreviations

AMPK: 5' adenosine monophosphate-activated protein kinase; AICAR: 5-aminoimidazole-4-carboxamide-1-B-D-ribofuranoside, AICA-riboside; DIOCC: 3,3′-dihexyloxacarbocyanine iodide; DMD: Duchenne muscular dystrophy; dMHC: Developmental myosin heavy chain; DMSO: Dimethyl sulfoxide; EDL: Extensor digitorum longus; Glut: Glutamine; LDH: Lactate dehydrogenase; mtDNA: mitochondrial Deoxyribonucleic acid; NADH: Nicotinamide adenine dinucleotide; NAO: 10-nonyl acridine orange; P/S: Penicillin / Streptomycin; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARδ: Peroxisome proliferator-activated receptor delta.
Competing interests
Dr. Nagaraju is one of the co-founders and member of the board of directors of ReveraGen BioPharma Inc, a biopharmaceutical company engaged in the discovery and development of proprietary, small molecule therapeutics for the treatment of neuromuscular diseases. This work was funded by Department of Defense USAMRAA grant W81XWH-05-1-0322 (Mouse Drug Screening Core to K. Nagaraju), the Foundation to Eradicate Duchenne, Inc, the Muscular Dystrophy Association, NIH grant R01-AR020478 (K. Nagaraju) and Cristal Ball funding. Dr. Hoffman is one of the co-founders and member of the board of directors of ReveraGen BioPharma Inc, a biopharmaceutical company engaged in the discovery and development of proprietary, small molecule therapeutics for the treatment of neuromuscular diseases. This work was funded by NIH grant T54HD053177-01A1 (Wellstone Muscular Dystrophy Center); R01-AR050478 (K. Nagaraju) and Cristal Ball funding.

The authors wish to acknowledge Dr. Deborah McClellan for editorial contributions. All authors read and approved the final manuscript.

Authors’ contributions
VEJ, PhD: designed research, conducted experiments, performed data analysis, and wrote the manuscript. JHM, PhD: conducted experiments, performed data analysis. HKU: conducted experiments, performed data analysis. TP, PhD: contributed to scientific discussion on the manuscript. EPF, PhD: provided reagents/lab facilities. KN, PhD: designed research, interpreted the data, provided reagents/lab facilities, wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
The authors wish to acknowledge Dr. Deborah McClellan for editorial assistance. Funding to KN in part by the Department of Defense USAMRAA grant W81XWH-05-1-0616 (Mouse Drug Screening Core); W81XWH-11-1-0782; National Institutes of Health grants K26RR032082; R01-AR050478 (KN);1U54HD053177-01A1 (Wellstone Muscular Dystrophy Center); W81XWH-11-1-0616 (Mouse Drug Screening Core to K. Nagaraju), and Muscular dystrophy association.

Author details
1Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC, USA. 2Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 3Integrative Systems Biology and Pediatrics, Research Center for Genetic Medicine Children’s National Medical Center, 111 Michigan Avenue, NW Washington, DC 20010, USA.

Received: 25 April 2012 Accepted: 23 July 2012

References
1. Freyssenet D: Energy sensing and regulation of gene expression in skeletal muscle. J Appl Physiol 2007, 102:529–540.
2. Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160–170.
3. Sandri M, Lin J, Hardinich C, et al: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 2006, 103:16260–16265.
4. Braut JJ, Jespersen JJ, Goldberg AL: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscular atrophy. Endocr J 2010, 57:1775–1785.
5. Angione AR, Jiang C, Pan D, Wang YX, Kuang S: PPARdelta regulates satellite cell proliferation and skeletal muscle regeneration. Skelet Muscle 2011, 1.
6. Selsby JT, Morini KJ, Pendrak K, Barton ER, Sweeney HL: Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One 2012, 7:e30063.
7. Grumati P, Coletto L, Sandri M, Bolognese P: Autophagy induction rescues muscular dystrophy. Autophagy 2011, 7:426–428.
8. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144:5179–5183. Epub 2003 Sep 5174.
9. Winder WW, Holmes BF, Rubinsk S, Jensen EB, Chen M, Holloszy JO: Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000, 88:2219–2226.
10. Tanaka T, Yamamoto J, Iwasaki S, et al: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003, 100:15924–15929. Epub 2003 Dec 15915.
11. Brunmar B, Staneck K, Doria J, et al: Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia 2006, 49:2713–2722.
12. Dresel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE: The peroxisome proliferator-activated receptor beta/delta agonist, GW505161, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 2003, 17:2477–2493. Epub 2003 Oct. E294.
13. Kramer DK, Al-Khabil L, Guigas B, Leng Y, Garcia-Roves PM, Krook A: Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007, 282:19313–19320.
14. Wang YX, Zhang CL, Yu RT, et al: Regulation of Muscle Fiber Type and Running Endurance by PPARdelta. PLoS Biol 2004, 2:e294.
34. Miura P, Chakkalakal JV, Boudreault L, et al. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. *Hum Mol Genet* 2009, 18:4640–4649.

35. Ljubicic V, Miura P, Burt M, et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. *Hum Mol Genet* 2011, 20:3478–3493.

36. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev* 2002, 82:291–329.

37. Tinsley JM, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. *Nat Med* 1998, 4:1441–1444.

38. Tinsley JM, Fairclough RJ, Storer R, et al. Daily Treatment with SMTc1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. *PLoS One* 2011, 6:e19189.

39. Cacchiarelli D, Incitti T, Martone J, et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. *EMBO Rep* 2011, 12:136–141.

40. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. *Am J Physiol Cell Physiol* 2007, 292:C188–C199.

41. Kamei Y, Miura S, Suzuki M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. *J Biol Chem* 2004, 279:41114–41123.

42. Tisdale MJ. Molecular pathways leading to cancer cachexia. *Physiology (Bethesda)* 2005, 20:340–348.

43. Kumar A, Boriek AM. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. *FASEB J* 2003, 17:386–396.

44. Porter JD, Guo W, Merriam AP, et al. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. *Neuromuscul Disord* 2003, 13:223–235.

45. Coll T, Alvarez-Guardia D, Barroso E, et al. Activation of peroxisome proliferator-activated receptor-(delta) by GW501516 prevents fatty acid-induced nuclear factor-(kappa)B activation and insulin resistance in skeletal muscle cells. *Endocrinology* 2010, 151:1560–1569.

doi:10.1186/2044-5040-2-16

Cite this article as: Jahnke et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. *Skeletal Muscle* 2012, 2:16.